Italian Biotech for Bioeconomy
Maria Luisa Nolli Assobiotec
Key Enabling Techonologies: un link tra ricerca pubblica e privata
Rome, December 5th 2012
Biotech is a KET
Source: European Commission Communication n. 512 “Preparing for our future: Developing a common strategy for key enabling technologies in the EU”, 2009
Given its prevalence and the significant increase in productivity that it is able to generate, biotechnology is fully included in the so-called Key Enabling Technologies (KET), as also defined by the European Commission. The prerogative of KET is, in fact, to increase the productivity of a system by improving the efficiency of existing processes.
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
The Biotech Industry Meta-sector
Innovation for Sustainable Growth
A growing number of companies operating in «traditional» sectors are integrating biotech products and technology in their production processes in order to improve the quality and the yeald, reducing the environmental impact
No process affect less the environment than natural processes from wich biotechnology derives
Bioeconomy is the challange that Europe is taking up for the estabilishment of a new model of sustainable development that can create value and employment
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Today in Europe bioeconomy is worth more than €2,000 bln and employs more than 22 mln people
Source: Ernst & Young – EuropaBIO 2012
Bioeconomy Impact in Europe
Estimated impact on Italian GDP
The European investment
Stima dell’impatto del biotech sul PIL italiano
…Coming to Horizon 2020, an important aim of the new programme for Research and Innovation for the period 2014-2020, is to address major societal challenges. Building the bio-economy is a prominent part of this approach. Industrial biotechnology and research and innovation activities in the field of bio-based industries have an essential role to play in this regard […] Maire Geoghegan Quinn, Lettera aperta a IFIB 2012
The European investment
EU Support for Innovation
France is the most supportive country for the innovation, whereas Italy still has room for improvement
Direct and indirect government contributions as GDP%
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012 (Italian version)
The Italian Biotech Sector
Companies Employees R&D employees Biotech turnover R&D investments
Total Pure Biotech
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
149 159178
199 211 223 228260
316
369396 394
0
50
100
150
200
250
300
350
400
450
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
394 52,060
6,872 7,075 mln€
1,830 mln€
248 8,330
2,499 1,278 mln€
557 mln€
Analysis by Application Field
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Pure biotech companies Total biotech companies
Small and Micro Companies are the Majority
Size > 80% small and micro < 20% medium 2% big
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Pure biotech companies by size
Geographic Distribution Total Biotech Companies Red Biotech Companies
Colocalization of smallµ pure biotech companies and STP
Biotech companies are mainly concentrated in northern and central Italy Lombardy is the region with the higest number of biotech companies -129
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
The red biotech drives the whole sector
Companies R&D employees Biotech turnover R&D investments
238 5.671
6,811 mln€ 1,691 mln€
141 1.638
1,080 mln€ 491 mln€
Total Pure Biotech
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Product analysis by development phase and type of company
Granted Orphan Drug Designation analysis
The Italian Pipeline
Therapeutic Areas The Italian population is the oldest
in the world: this makes Italy an increasingly interesting scenario for those companies intending to develope and conduct clinical trails on new drugs for the treatment of age-related diseases
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Advanced Therapies
Companies Biotech turnover
33 882 mln€
Geographical distribution
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Green Biotech
By 2015 about half of the global production of food, feed and industrial seeds will be derived from plant varieties developed using one or more biotechnology applications
In the field of agro-biotechnology Italy can count on absolutely unique conditions in its variety of microclimates, biodiversity, and potential market niches
Hence the importance of agro-food diagnostics, for the certification of origin and authenticity of the many Made in Italy products appreciated throughout the world.
Green Biotech
Agro-biotechnology uses modern biotech methods in many applications ranging from improving specific plant varieties, to checking the origin and quality of food and extracting bioactive substances which are available in nature only to a limited extent (molecular pharming).
Companies R&D employees Biotech turnover R&D investments
82 745
103 mln€ 111 mln€
62 431
40 mln€ 41 mln€
Total Pure Biotech
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
White Biotech
Industrial biotechnology uses enzymes and micro-organisms to develop bioproducts in various sectors such as, among others, chemical, paper, textile and bioenergy. The use of renewable raw materials represents in effect one of the most innovative and promising approaches to reduce greenhouse gas emissions
White technologies also allow significant improvement in the output of industrial processes and the value of production in itself, with considerable advantages in terms of economy and environmental protection.
According to OECD estimates, in 2030 industrial and agro-biotechnology will represent overall 75% of the gross added value of the biotech sector
Companies R&D employee Biotech turnover R&D investments
54 456
161 mln€ 28 mln€
40 430
157 mln€ 25 mln€
Total Pure Biotech
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
White Biotech
► Biospecialities: food ingredients, pharmaceuticals, fine chemicals Pharma
► Biospecialities ► Biomaterials: biopolymers, lubrificants, fibers, pigments, protein ► Sugars, Lipids, Proteins, other chemicals: fatty acids, aminoacids, phenols,
antioxidants, fibers, pigments
► Biomaterials ► Base Chemicals: organic acids, I & II metabolites
Cosmesi
Chimico Tessile
► Biofuels: Ethanol, Methane, Hydrogen ► Bioremediation: enzymes, microorganism
Energy – Fuels Bioremediation
Sect
or o
f app
licat
ion
1
2
3
4
The Transversality of the White Biotech
Scientific and Technological Parks
A significant number of pure biotech companies are located within STPs
encouraging the development of true centres of aggregation of researchers, companies and investors
guarantee a network of excellence and consulting services, as well as promotion and support activities for fundraising purpose
acting as intermediaries between the demand for skills and the availability of innovation and financial resources
Source: Ernst & Young – Assobiotec, BioInItaly Report 2012
Industry’s Requirements
High research quality
the poor economic resources for the academic research should be focussed on: the best research teams such ongoing research fields in which Italy could be
effectively competitive on an international level
Valorization of research results
the research projects should fulfill all the requirements to be valorized and transferred to the market - no disclosure before a patent application
a certain Intellectual Property to guarantee a faster negotiation and technology transfer
Networking Market Requirements
Cooperation between different players it is necessary
The bioindustry & pharma associations can act as cluster ‘promoters’
For further info:
www.assobiotec.it
THANKS FOR YOUR ATTENTION
Top Related